Loading candles…
Supriya Lifescience Ltd., headquartered in Mumbai, India, was initially established as a partnership in 1987 and later incorporated as a public limited company in 2008. The company operates in the pharmaceutical industry, specializing in the manufacturing and export of Active Pharmaceutical Ingredients (APIs). Its portfolio includes 38 APIs focused on therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic, and anti-allergic. Supriya Lifescience follows a backward-integrated business model supported by a specialized manufacturing facility and dedicated research and development capabilities. The company serves markets across India and exports to over 120 countries globally. It is recognized as a niche player within the global regulated life science sector.
This page is a live market overview for SUPRIYA LIFESCIENCE LTD (SUPRIYA) on the NSE. As a listed security, SUPRIYA LIFESCIENCE LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SUPRIYA before placing trades on tick2trade.
As of the latest feed, SUPRIYA last traded at ₹923.45 on NSE, up ₹32.6 (3.66%) from the previous close of ₹890.85. Today's session range is ₹891.7 – ₹928, against a 52-week band of ₹545.5 – ₹1,085. Traded volume today stands at 2.34L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SUPRIYA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SUPRIYA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SUPRIYA LIFESCIENCE LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SUPRIYA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SUPRIYA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 13 Aug 2026 |
| Audited Results - Q4 & FY26 | Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2026 And Recommend Dividend, If Any, On The Equity Shares Of The Company Fo… | 27 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 9 Feb 2026 |
| Unaudited Results - Q2 & FY25 | In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this to inform you that a meeting of the Board of Dire… | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 27 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.